Global Insulin Market
市场规模(十亿美元)
CAGR : %
Forecast Period |
2024 –2031 |
Market Size (Base Year) |
USD 19.97 Billion |
Market Size (Forecast Year) |
USD 27.12 Billion |
CAGR |
|
Major Markets Players |
>全球胰岛素市场细分,按产品类型(中效胰岛素、短效胰岛素、速效胰岛素和长效胰岛素)、来源(人重组胰岛素和胰岛素类似物)、疾病类型(1 型糖尿病、2 型糖尿病、妊娠糖尿病和前驱糖尿病)、输送设备(注射器、注射笔、泵等)、最终用户(家庭医疗保健、医院、非处方 (OTC)、诊所等)– 行业趋势和预测到 2031 年
胰岛素市场分析
胰岛素市场是全球糖尿病护理行业的一个重要领域,其驱动因素是糖尿病(尤其是 1 型和 2 型糖尿病)患病率的上升。随着技术的进步和对个性化医疗的日益关注,市场正朝着创新型胰岛素制剂和给药设备的方向发展,包括胰岛素笔、胰岛素泵和智能胰岛素系统。最近的发展突显了重大进展,例如新生物制剂的接受和速效胰岛素类似物的引入,提高了治疗效果和患者依从性。此外,新兴市场对胰岛素的需求不断增加,加上医疗基础设施的改善,带来了巨大的增长机会。对持续血糖监测和综合糖尿病管理系统的重视进一步推动了市场增长。总体而言,在持续创新和对有效糖尿病管理的高度关注的推动下,胰岛素市场有望持续扩张。
胰岛素市场规模
2023 年全球胰岛素市场规模价值为 199.7 亿美元,预计到 2031 年将达到 271.2 亿美元,2024 年至 2031 年预测期内的复合年增长率为 3.90%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外,Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。
胰岛素市场趋势
“生物仿制药胰岛素的创新 ”
The insulin market is evolving rapidly, influenced by rising diabetes prevalence and advancements in treatment technologies. Innovations such as biosimilar insulins and smart delivery devices are enhancing patient compliance and outcomes. One prominent trend is the increasing adoption of insulin pens and pumps, which offer convenience and precision in diabetes management. These devices enable patients to administer doses more accurately, leading to better glycemic control. Furthermore, the integration of digital health solutions, including continuous glucose monitoring systems, is reshaping diabetes care by providing real-time data for personalized treatment plans. Overall, the insulin market is characterized by ongoing innovation, focusing on improving patient experience and outcomes while addressing the growing global demand for effective diabetes management solutions.
Report Scope and Insulin Market Segmentation
Attributes |
Insulin Key Market Insights |
Segments Covered |
|
Countries Covered |
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America. |
Key Market Players |
Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon (India), Julphar (UAE), Ypsomed AG (Switzerland), BD (U.S.), Wockhardt Ltd. (India), B. Braun SE (Switzerland), Biodel AG Inc. (U.S.), Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (China), Tonghua Dongbao Pharmaceutical Co., Ltd. (China) |
Market Opportunities |
|
Value Added Data Infosets |
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework. |
Insulin Market Definition
Insulin is a hormone produced by the pancreas that regulates blood sugar (glucose) levels in the body. It allows cells to absorb glucose from the bloodstream to use as energy or store for later use. Insulin helps maintain blood sugar levels within a narrow range, preventing hyperglycemia (high blood sugar) and hypoglycemia (low blood sugar). Its deficiency or improper function leads to conditions such as diabetes. In individuals with diabetes, insulin therapy may be required to help control glucose levels.
Insulin Market Dynamics
Drivers
- Rising Incidence of Diabetes
The rising incidence of diabetes worldwide, particularly Type 1 and Type 2 diabetes, is a significant driver of demand for insulin therapies. According to the International Diabetes Federation, the number of people living with diabetes continues to grow rapidly, with millions diagnosed each year. This surge is attributed to various factors, including sedentary lifestyles, unhealthy dietary habits, and genetic predispositions. As more individuals are diagnosed, the need for effective management solutions, including insulin, becomes critical to controlling blood glucose levels and preventing complications associated with diabetes. Consequently, healthcare providers are increasingly prescribing insulin therapies to meet the growing patient demand. This trend underscores the importance of addressing diabetes as a major public health issue and highlights the vital role of insulin in improving patient outcomes.
- Rising Healthcare Expenditure
Increased healthcare spending, especially in developing regions, plays a crucial role in enhancing access to diabetes management solutions, including insulin therapies. As countries invest more in their healthcare infrastructure, there is a greater focus on improving patient care and expanding the availability of essential medications. This uptick in spending allows for better distribution of insulin products and related diabetes management technologies, facilitating easier access for patients who need them. Moreover, improved healthcare systems can support diabetes education initiatives, empowering patients to manage their conditions more effectively. This increased accessibility promotes adherence to prescribed insulin therapies and contributes to better overall health outcomes for individuals with diabetes.
Opportunities
- Integration of Digital Health Technologies
The integration of digital health technologies, including mobile applications and continuous glucose monitoring (CGM) systems, offers significant opportunities for the development of comprehensive diabetes management solutions that incorporate insulin therapy. These technologies enable patients to track their blood glucose levels in real time, allowing for more precise adjustments to insulin dosages based on their daily activities and dietary choices. Mobile apps can facilitate seamless communication between patients and healthcare providers, fostering better adherence to treatment plans and promoting proactive management of diabetes. In addition, the data collected through these digital tools can help healthcare professionals tailor insulin regimens to individual patient needs, ultimately improving outcomes. As digital health continues to evolve, it presents a transformative opportunity to enhance diabetes care and optimize insulin therapy for better patient quality of life.
- Innovative Delivery Systems
The growing demand for convenient and user-friendly insulin delivery devices, such as smart insulin pens and inhaled insulin, presents significant opportunities for product development and market differentiation. Patients increasingly seek solutions that simplify the process of administering insulin while improving accuracy and reducing discomfort. Smart insulin pens, equipped with digital features such as dosage tracking and reminders, enhance adherence and empower users to manage their diabetes more effectively. Similarly, inhaled insulin offers a needle-free alternative that caters to those apprehensive about injections, providing an appealing option for many patients. As manufacturers focus on innovation to meet these evolving preferences, they can capitalize on the market's demand for advanced delivery systems. This shift fosters patient satisfaction and creates a competitive edge for companies willing to invest in the development of these cutting-edge solutions.
Restraints/Challenges
- High Costs of Insulin
The rising prices of insulin and related products present substantial barriers for patients, significantly impacting their ability to manage diabetes effectively. As insulin costs increase, many individuals may find themselves unable to afford their necessary medications, leading to decreased adherence to prescribed therapies. This non-adherence can result in poorly controlled blood glucose levels, heightening the risk of severe complications such as cardiovascular disease, neuropathy, and kidney damage. Furthermore, the financial strain may force patients to make difficult choices between their medications and other essential needs, exacerbating health disparities. As a consequence, the overall burden of diabetes management increases, placing additional strain on healthcare systems. Addressing the issue of high insulin prices is crucial to ensure that all patients have access to the necessary treatments for effective diabetes management and improved health outcomes.
- Shortage Limited Treatment Options
Despite significant advancements in diabetes care, the range of effective treatment options for insulin therapy remains relatively narrow, posing a substantial restraint on the market. Many patients with Type 1 and Type 2 diabetes rely primarily on traditional insulin formulations, which can limit their ability to tailor treatment plans to their specific needs. This lack of diversity in treatment options can hinder effective blood glucose management, leading to dissatisfaction and decreased adherence to prescribed therapies. Furthermore, patients may struggle to find suitable alternatives when they experience adverse effects or inadequate responses to existing insulin products. Consequently, this limitation can restrict patient choice and flexibility in managing their condition, ultimately impacting overall health outcomes. Expanding the variety of effective treatment options is essential to enhance patient empowerment and optimize diabetes management strategies.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Insulin Market Scope
The market is segmented on the basis of product type, source, disease type, delivery devices, end users. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Intermediate Acting Insulin
- Short Acting Insulin
- Rapid Acting Insulin
- Long Acting Insulin
Source
- Human Recombinant Insulin
- Insulin Analogs
Disease Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Prediabetes
Delivery Devices
- Syringes
- Pens
- Pumps
- Others
End Users
- Home Healthcare
- Hospitals
- Over The Counter (OTC)
- Clinics
- Others
Insulin Market Regional Analysis
The market is analysed and market size insights and trends are provided by country, product type, source, disease type, delivery devices, end users as referenced above.
The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America leads the insulin market, primarily driven by the high prevalence of diabetes among its population. In addition, the region is characterized by robust research activities aimed at advancing diabetes treatment, coupled with a diverse array of manufacturers contributing to the market. This combination of factors solidifies North America's position as a dominant force in the insulin sector.
Asia-Pacific region is projected to experience the highest growth rate in the insulin market from 2024 to 2031, driven by an increasing geriatric population and a rising incidence of diabetes. In addition, heightened awareness of the benefits of insulin therapy among the public, coupled with substantial investments in developing advanced and innovative products, further fuels this growth. These factors collectively position Asia-Pacific as a key player in the expanding insulin market.
报告的国家部分还提供了影响单个市场因素和国内市场监管变化,这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外,在提供国家数据的预测分析时,还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。
胰岛素市场份额
市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。
在市场上运营的胰岛素市场领导者是:
- 赛诺菲(法国)
- 诺和诺德公司(丹麦)
- 礼来公司 (美国)
- Biocon(印度)
- 阿联酋海湾药业
- Ypsomed AG(瑞士)
- BD(美国)
- Wockhardt Ltd.(印度)
- B. Braun SE(瑞士)
- Biodel AG Inc.(美国)
- 上海复星医药(集团)股份有限公司 (中国)
- 通化东宝药业有限公司 (中国)
胰岛素市场最新动态
- 2023 年 9 月,诺和诺德宣布与 Aspen Pharmacare Holdings Limited 和 Aspen SA Operations (Pty) Ltd 合作,在南非建立人体胰岛素生产基地。此次合作旨在增强当地的制造能力,确保更可靠的胰岛素供应,以满足该地区日益增长的需求。通过投资当地生产,该合作伙伴关系旨在改善南非患者获得胰岛素治疗的机会
- 2022 年 11 月,美国 FDA 批准 Rezvoglar,使其成为糖尿病患者第二个可互换的甘精胰岛素生物仿制药。该批准旨在扩大治疗选择并提高糖尿病患者的可及性。通过将 Rezvoglar 引入市场,患者可以从更实惠的替代品中受益,同时确保有效的血糖控制
- 2022 年 4 月,Biocon 与马来西亚卫生部签订了一份为期三年、价值 9000 万美元的合同,用于供应重组人胰岛素 Insugen。这份重要的合同不仅巩固了 Biocon 在马来西亚市场的地位,还凸显了该公司致力于提高新兴市场获得基本糖尿病治疗的机会。通过扩大其在马来西亚的业务范围,Biocon 旨在满足日益增长的胰岛素需求并改善该地区患者的治疗效果
- 2022 年 2 月,Biocon 宣布与 Viatris Inc. 达成战略合作,收购 Viatris 的生物仿制药业务。此次合作旨在加强 Biocon 的研发工作并增强其制造能力。通过整合 Viatris 的专业知识,Biocon 寻求加强其在生物仿制药市场的地位并加速创新疗法的商业化
- 2021 年 11 月,Biocon 与印度糖尿病研究协会 (RSSDI) 合作,推出了一项旨在支持 1 型糖尿病患者的综合护理计划。该计划不仅为有效的糖尿病管理提供了宝贵的资源和指导,还加强了 Biocon 对改善患者治疗效果的承诺。通过积极参与此类计划,Biocon 提升了其品牌形象并巩固了其在糖尿病护理市场的地位。
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
研究方法
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
可定制
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.